patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) beta variant (B.1.351 / 501Y.V2, South Africa) delta variant (B.1.617.2, Indian) elderly (typically over 65yr) positive for SARS-Cov-2 at baseline
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Non replicating viral vector - versus placebo - for COVID-19 prophylaxis (excluding children)
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 confirmed Covid-19, from 1st dose 0.27 [0.20, 0.36]< 1 0% 1 study (1/-) 100.0 % NA not evaluable crucial - deaths 0.19 [0.04, 0.81]< 1 0% 1 study (1/-) 98.7 % NA not evaluable crucial - hospitalization 0.18 [0.03, 1.17]< 1 0% 1 study (1/-) 96.3 % NA not evaluable important - symptomatic Covid-19 0.33 [0.27, 0.41]< 1 0% 1 study (3/-) 100.0 % NA not evaluable important - severe COVID-19 occurrence 0.23 [0.11, 0.48]< 1 0% 1 study (2/-) 100.0 % NA not evaluable non important - safety endpoints 00 adverse events 1.61 [1.52, 1.71]< 1 2% 3 studies (3/-) 0.0 % NA not evaluable non important - ATE (Myocardial infarction or ischemic stroke) 0.50 [0.12, 2.00]< 1 0% 1 study (3/-) 83.6 % NA not evaluable non important - deep vein thrombosis 3.00 [0.61, 14.86]< 1 0% 1 study (1/-) 9.0 % NA not evaluable non important - Guillain-Barré syndrome 1.00 [0.06, 15.98]< 1 0% 1 study (2/-) 50.0 % NA not evaluable non important - intracranial hemorrhage 0.28 [0.04, 1.81]< 1 0% 4 studies (4/-) 90.9 % low not evaluable high non important - ischemic stroke 0.67 [0.11, 3.99]< 1 0% 1 study (6/-) 67.1 % NA not evaluable non important - Myocardial infarction 1.00 [0.02, 50.39]< 1 0% 1 study (7/-) 50.0 % NA not evaluable non important - pericarditis 2.00 [0.07, 59.60]< 1 0% 1 study (1/-) 34.7 % NA not evaluable non important - pulmonary embolism 4.00 [0.45, 35.79]< 1 0% 1 study (7/-) 10.9 % NA not evaluable non important - serious adverse events (SAE), any 0.98 [0.71, 1.34]< 1 0% 4 studies (4/-) 56.0 % NA not evaluable non important - venous thromboembolism 2.75 [0.88, 8.64]< 1 0% 1 study (1/-) 4.2 % NA not evaluable non important - AE of interest endpoints 00 cerebral venous sinus thrombosis (CVST) 2.00 [0.07, 59.60]< 1 0% 1 study (1/-) 34.7 % NA not evaluable important - appendicitis 1.20 [0.37, 3.93]< 1 0% 1 study (1/-) 38.2 % NA not evaluable non important - Bell's palsy 1.50 [0.25, 8.98]< 1 0% 1 study (2/-) 32.9 % NA not evaluable non important - reactogenicity (vaccines) endpoints 00 systemic adverse reaction, any, dose 1 20.24 [10.60, 38.63]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - systemic adverse reaction, any, dose 2 4.39 [2.05, 9.41]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.